Stock Ratings / Health Care / GELS / options

BGMS (40) PCSA (48) LGVN (32) PULM (36) ⌘ Pro Terminal →

Gelteq Limited (GELS) Options Positioning, Max Pain & Unusual Sweeps

$0.51 +5.11% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.51

Gelteq Limited (GELS) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $5.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.51 (+0.73%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE+0% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GELS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (59/100 Composite)

🔍 WHY GELS SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$0.52-13.5% Next Q

Q2 (-2Q)

Grade C+$0.45-4.4% Next Q

Q3 (-1Q)

Grade C+$0.43+18.6% Next Q

Current

Grade C-$0.51+0.2% Hist 90D α

Trajectory: B- (67) → C- (59)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the GELS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, GELS faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($0.56) or 200D SMA ($0.66) invalidates the momentum regime and cuts Target Base ($0.51) toward Bear Floor ($0.40).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GELS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “GELS Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 59%NO 41%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (GELS)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for GELS.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating GELS & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on GELS
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GELS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.31%⚡ TESTING RESISTANCE

2026-10-30O $0.48H $0.51L $0.45C $0.51VOL 26.2K

RES: $0.53SUP: $0.43SMA50: $0.56SMA200: $0.66

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GELS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GELS Butterfly Map → + Track GELS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GELS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GELS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GELS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GELS)

Health Care Rank #217 of 1016 ⚔️ BGMS vs GELS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GELS vs. BGMS, PCSA, LGVN, PULM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Gelteq Limited (GELS) ranks #217 by composite RQD confidence (59/100, grade C-) and #938 by equity capitalization ($5.4M). Within this direct 5-issuer industry benchmark cohort, GELS leads on earnings valuation at N/A trailing P/E, while BGMS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GELS currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GELS ACTIVE Gelteq Limited	C-	59/100	—	—	—	+5.11%	$5.4M	Benchmark Subject
BGMS Bio Green Med Solution Inc.	D-	40/100	—	—	-35.0%	-9.79%	$5.5M	/bgms-vs-gels →
PCSA Processa Pharmaceuticals Inc.	D	48/100	—	—	-35.0%	+2.16%	$5.3M	/pcsa-vs-gels →
LGVN Longeveron Inc. (Class A)	E	32/100	—	67.0%	-35.0%	-1.68%	$5.6M	/lgvn-vs-gels →
PULM Pulmatrix Inc.	D-	36/100	—	—	-35.0%	-5.67%	$5.2M	/pulm-vs-gels →

2. GELS Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Gelteq Limited (GELS) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $5.4M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. GELS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GELS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Gelteq Limited (NASDAQ: GELS) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $0.51 (+5.11% 1D, market cap $5.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, GELS ranks #217 in composite RQD confidence.

How does GELS compare to BGMS and PCSA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GELS carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, BGMS (Bio Green Med Solution Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $5.5M) and PCSA (Processa Pharmaceuticals Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, GELS leads on earnings multiple (N/A) while BGMS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GELS?

For Gelteq Limited (GELS), key quantitative strengths include Big institutional funds and options desks are actively positioning on the bullish side. and sector rank #217 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GELS trading relative to its 50-day, 200-day, and 52-week technical levels?

GELS last traded at $0.51 (+5.11% on volume of 77,208 shares), positioning the stock -8.93% below its 50-day simple moving average ($0.56) and -22.73% below its 200-day simple moving average ($0.66). Across its 52-week range of $0.39 to $2.01, GELS sits at the 7.4% percentile with a 14-day RSI of 48.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.57).

GELS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is GELS's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for GELS.

Direct Sub-Reports: GELS RQD Cockpit GELS 12M Forecast GELS Earnings & Move GELS Dividends & DRIP GELS Insiders & 13F GELS Whale Options GELS Profit Sankey GELS News & Why